EGFR and non-small cell lung carcinoma: The results of the Phase III FLAURA study (NCT02296125)[9] in patients with newly diagnosed advanced NSCLC and central nervous system metastasis showed a median progression-free survival (PFS) of 13.9 months following treatment with first-generation EGFR-TKIs (gefitinib or erlotinib) and >16.5 months with osimertinib.